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a  b  s  t  r  a  c  t
Interference  from  transplacental  and  breast  milk  antibodies  may  impede  the  performance  of  oral  live
vaccines.  The  effect  of breastfeeding  on  the  immunogenicity  of Rotarix®, a two-dose  oral  monova-
lent  rotavirus  vaccine,  was  examined  in  a community-based  trial in New  Delhi, India.  Four  hundred
mother–infant  pairs  were  randomized  into  two  equal  groups.  Infants  were  aged  6–7  weeks  at  enroll-
ment.  Mothers  were  encouraged  to either  breastfeed  or to  withhold  breastfeeding  during  the  30  min
prior  to and  after  each  vaccine  dose  was  administered.  We  collected  blood  specimens  from  infants  at
enrollment  and  4 weeks  after  the second  vaccine  dose.  Blood  and  breast  milk  specimens  were  obtained
from  mothers  at  baseline  and  breast  milk  specimens  were  collected  at the  time  of the second  vaccine
dose.  Seroconversion  was  deﬁned  as infant  serum  anti-VP6  IgA antibody  level  of ≥20  IU/mL  4  weeks
after  the  second  vaccine  dose  and a ≥4-fold  rise  from  baseline.  There  was  no  difference  in  the  propor-
tion  who  seroconverted  between  the  two  groups  (26%  vs  27%;  p =  0.92).  The  levels  of  infant  serum  IgA,
maternal  serum  and  breast  milk  IgA  and  IgG  anti-rotavirus  antibodies  predicted  the  anti-rotavirus  IgA
level in  infants  at end-study  and  explained  approximately  10%  of the  variability  of  the  immune  response
2(r = 0.10,  p  <  0.001).
In this  population,  the  immune  response  to Rotarix® was  not  enhanced  by  withholding  breastfeeding
around  the  time  of vaccination.  Maternal  anti-rotavirus  antibodies  explained  little  of  the  variability  in the
immune  response  to the vaccine.  Factors  other than  maternal  anti-rotavirus  antibodies  probably  explain
why infants  in low-and  middle-income  settings  respond  poorly  to  live  oral  rotavirus  vaccines.
© 2014  Published  by Elsevier  Ltd.  This is an  open  access  article  under  the  CC  BY-NC-ND  license. IntroductionRotavirus is the leading cause of fatal and severe diarrhea in
hildren [1]. In India, it is responsible for almost 100,000 deaths
 Trial registration: Clinical Trial Registry-India (CTRI/2012/10/003057), Clinical-
rials.gov (NCT01700127).
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annually [2]. The WHO  has recommended inclusion of rotavirus
vaccines in all national immunization programs. Currently there are
two licensed rotavirus vaccines available; Rotarix®, GSK Biologicals
and RotaTeq®, Merck & Co. Both vaccines have demonstrated high
efﬁcacy (>90%) against severe rotavirus diseases and rotavirus asso-
ciated hospitalization in clinical trials in high- and middle-income
countries [3–5]. However, trials of these two vaccines conducted
in developing settings in Africa and Asia showed lower efﬁcacy,
of approximately 60% [6–9]. Most recently, the indigenously man-
ufactured live, oral 116E monovalent human–bovine vaccine has
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oon. The efﬁcacy of the 116E vaccine was 54% [10] which is similar
o that of Rotateq® and Rotarix® in these settings.
Other live oral vaccines have also performed poorly in low-
ncome countries as compared to more afﬂuent countries [11].
urrent evidence indicates that decreased vaccine performance
ould be attributed to several factors including child or mater-
al malnutrition, environmental enteropathy, interference from
aternal antibodies and presence of other intestinal infections
11]. Presence of rotavirus antibodies in breast milk and transpla-
ental maternal antibodies is associated with impaired responses to
otavirus vaccines [12–14]. Indian women seem to have higher con-
entrations of rotavirus neutralizing antibodies in breast milk than
omen in industrialized countries [15]. In vitro studies of the neu-
ralizing effect of breast milk have suggested that withholding of
reastfeeding around the time of rotavirus vaccine administration
ould improve the immune response to the vaccine [15].
Previous trials of rotavirus vaccines had not shown any differ-
nce in the immune response to vaccine regardless of whether
reast milk was given or not at the time of vaccine administra-
ion. In those trials information on breastfeeding was available,
owever, breastfeeding was self-reported by mothers and the dura-
ion between breastfeeding and vaccination was  not adequately
ssessed [16,17]. A recent study from South Africa reported that
bstention from breastfeeding an hour before and after each vac-
ination had no substantial effect on the immune response to a
otavirus vaccine in HIV-uninfected infants [18].
Without clear evidence, it is difﬁcult to determine whether
otavirus antibodies in breast milk interfere with immune response
o oral rotavirus vaccines in infants. It is important to explore this
ssociation, as it may  help improve the impact of the vaccines. We
herefore measured whether withholding breastfeeding around the
ime of vaccination with Rotarix® would improve its immunogenic-
ty. We  also explored the association between maternal serum
nd breast milk anti-rotavirus antibody concentrations with the
mmune response in infants after two doses of this vaccine.
. Material and methods
.1. Study design and participants
The trial was conducted in typical urban resettlement neighbor-
oods of South Delhi, India.
Infants aged less than 7 weeks were identiﬁed through a house-
old survey. Families of infants aged 6–7 weeks were invited to
he study clinic for screening and enrollment. Informed written
onsent was obtained from all parents and also speciﬁcally from
he mothers. All enrolled infants received two doses of Rotarix® at
–7 weeks and at 10–14 weeks of age along with other childhood
accines (Diphtheria, Pertussis, Tetanus, Haemophilus inﬂuenzae
, Hepatitis B and oral Polio).
At the study clinic after consent was obtained, a physician exam-
ned the infant. Mother–infant pairs were enrolled if the parents
ave consent, infants were aged 6–7 weeks, the weight for age was
−3SD of the WHO  child growth standards, and the family had no
lans to move out of the study area for the next 4 months. Infants
ere excluded if they were not breastfed, had already received a
otavirus vaccine, had immunodeﬁciency disease, chronic enteric
isease, and/or any other condition as warranting exclusion by the
nvestigator. Infants were temporarily excluded if they had diarrhea
r any illness requiring hospital referral on the day of enrollment.
Eligible infants were either allocated to the group where moth-
rs were requested to withhold breastfeeding for 30 min  before and
fter vaccine administration or to the group where mothers were
ncouraged to breastfeed their infants around the time of vacci-
ation. There were two separate locations in the study clinic forine 32S (2014) A134–A139 A135
the two groups to ensure that instructions for breastfeeding were
followed by mothers. Clinical coordinators supervised each area.
Activities were conducted in the following order: 30 min  of with-
holding or encouraging breastfeeding; administration of Rotarix®;
30 min  of withholding or encouraging breastfeeding; administra-
tion of other childhood vaccines; observation for 30 min  to assess
for immediate adverse events. The study team documented the
time breastfeeding started and ended as well as the time when the
other vaccines were administered.
2.2. Follow-up activities
Infants were observed for immediate adverse events in the study
clinic and referred to the hospital, if required. Families of infants
were contacted weekly after each dose of the Rotarix® to ascertain
presence of signs and symptoms of any illness requiring hospital
referral including intussusception, or other serious adverse events.
Minor illnesses not requiring hospital referral were managed by
the study physician. Serious adverse events were reported to the
relevant Ethics Committees.
2.3. Randomization and blinding
The randomization list was generated by a statistician inde-
pendent of the study team in Stata 11 (StataCorp LP, TX, USA).
Eligible infants were randomly allocated to either group through
serially numbered opaque sealed envelopes with the group allo-
cation written inside the envelope. The laboratory assessing the
immune responses was  blinded to the group allocation.
2.4. Assessment of immune response
At enrollment, blood and breast milk specimens were obtained
from mothers and blood and stool specimens were obtained from
the infants. At the time of the second dose of Rotarix®, a breast
milk specimen was  obtained from the mother. Four weeks after
the second dose of Rotarix®, blood specimen was  obtained from
each infant.
2.5. Laboratory methods
The specimens were tested at the Wellcome Trust Research Lab-
oratory at Christian Medical College, Vellore. The IgA and IgG titers
were determined by comparing the optical density values form
sample wells with the standard curve based on derived units of IgA
arbitrarily assigned to pooled human serum samples, as previously
described [19].
2.6. Statistical analyses
Statistical analyses were carried out in Stata 11.0 (StataCorp LP,
TX, USA). Descriptive measures of continuous variables were pre-
sented as means and standard deviations for symmetrical data, and
as medians and interquartile ranges for skewed data. The Spearman
rank-order correlation test was used for comparing median values.
Seroconversion was deﬁned as infant serum anti-VP6 IgA antibody
level of ≥20 IU/mL 4 weeks after the second vaccine dose and a ≥4-
fold rise from baseline. We  measured the effect of the interventions
and other exposures on the proportion who  seroconverted and on
the log-transformed end study antibody levels of the infants. The
relationship between maternal and child antibodies and these out-
comes were examined in crude and multivariate logistic and linear
regression models. In these models, we initially included variables
that were signiﬁcant on a 0.05 level (from the crude models), we
kept those that remained signiﬁcant and added the other exposure
variables one at a time and retained signiﬁcant variables for the
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nal model. The ratio between proportions and its corresponding
onﬁdence interval was calculated using the binreg command in
tata.
.7. Ethical considerations
Ethical clearance was obtained from Society for Applied Studies,
thics Review Committee, Christian Medical College, Institutional
thics Committee and South-East Regional Ethical Committee of
orway. This study was conducted in compliance with the protocol,
ood Clinical Practices and other relevant regulatory guidelines.
. Results
Of the 533 infants screened for eligibility, 400 were enrolled
nd randomized into two equal groups. All infants received the ﬁrst
ose of Rotarix® and 391 received both doses; four families moved
ut of the study area and ﬁve refused the second dose (Fig. 1).
Both baseline and end study blood specimen were available for
88 infants.
The baseline characteristics were comparable between the
roups (Table 1). The proportion of infants being exclusively breast-
ed was high overall; 75% in the group that was requested to
ithhold breastfeeding around the time of vaccination and 80% in
he group that was encouraged to breastfeed. The mean (SD) age
f infants at the time of vaccination was 6.9 (0.56) and 11.2 (0.62)
onths for the ﬁrst and second doses, respectively.
The infant and maternal anti-rotavirus antibody levels in the
erum and breast milk were similar between the two groups
Table 2). All except one mother in the group that was withhold-
ng breastfeeding adhered to the instructions. Infants in the group
ithholding breastfeeding were not breastfed for a mean (SD) dura-
ion of 49 (11.1) and 46 (10.9) min  after receiving the ﬁrst and
econd doses of Rotarix®, respectively.
The proportions of infants who seroconverted at study end were
imilar in the two groups; 26% of infants in the group where breast-
eeding was withheld and 27% in the group where infants were
reastfed (p = 0.920) (Table 3). The ratio of the proportion that
eroconverted in the two groups was 0.98 (95% CI 0.70, 1.38). The
able 1
aseline characteristics of participants in the two study groups.
Infant characteristics
Age at enrollment (days)
Mean (SD)
Birth  weighta (kg)
Mean (SD)














Mothers who  have not attended school 
Fathers who have not attended school 
Family who own color TV, cooler, or scooter 
Annual  family income, kRupees median/inter quartile range 
ll are n (%) except when speciﬁed otherwise.
a Reliable information on birth weight was available for 137 (68.5%) infants in the with
reastfeed.Fig. 1. Trial proﬁle.
maternal serum IgA and IgG at baseline and breast milk IgA and
IgG were also signiﬁcantly associated with the immune response
(Table 4). While the infant baseline antibody level was  positively
associated, maternal antibodies were negatively associated with
the immune response. The adjusted model, including infant base-
line serum IgA, breast milk IgA and breast milk IgG conﬁrmed these
associations (Table 4).The odds (95% CI) of seroconversion showed similar results
with higher odds of seroconversion with increasing levels of infant
Breastfeeding withheld (n = 200) Breastfeeding encouraged (n = 200)
48 (4.0) 49 (3.8)
2.8 (0.4) 2.8 (0.5)
4.4 (0.6) 4.4 (0.5)
97 (48.5) 95 (47.5)
150 (75.0) 160 (80.0)
61 (30.5) 52 (26.0)
112 (56.0) 115 (57.5)
88 (44.0) 85 (42.5)
0.95 (0.96) 1.1 (1.1)
24.4 (3.5) 24.8 (3.9)
48 (24.0) 45 (22.5)
22 (11.0) 22 (11.0)
182 (91.0) 179 (89.5)
84 (60, 120) 84 (72, 120)
holding of breastfeeding group and 143 (71.5%) infants in the group encouraged to
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Table  2
Infant and maternal anti-rotavirus antibody concentrations in breastfeeding encouraged and withheld infants (log IU).
Breastfeeding withheld Breastfeeding encouraged
Median (IQR) Median (IQR)
Infant
Serum IgA baseline 1.95 (0.33, 5.48) 2.04 (0.59, 4.37)
Serum IgA post dose 2 6.77 (1.95, 35.38) 6.06 (1.72, 29.02)
Maternal
Serum IgA baseline 210.19 (105.16, 384.56) 164.99 (94.96, 371.05)
Serum IgG baseline 11,562.03 (5402.71, 20,575.12) 9801.49 (4577.05, 23,997.40)
Breast milk IgA baseline 17.63 (9.13, 44.16) 18.23 (9.68, 36.63)
Breast milk IgG baseline 14.26 (0.00, 52.79) 15.85 (0.00, 46.13)
Breast milk IgA at dose 2 17.46 (9.44, 34.81) 17.43 (9.22, 28.94)
Breast milk IgG at dose 2 16.69 (0.00, 46.66) 15.82 (0.00, 53.50)
p > 0.05 for all comparisons.
Table 3
Immune responses four weeks after dose 2 of Rotarix® in seronegative infants (serum anti- rotavirus IgA < 20 IU/mL at baseline).
Breastfeeding withheldN = 172 Breastfeeding encouragedN = 184 p value
4-Fold rise (seroconversion)aN % 45 (26.1) 49 (26.6) 0.92
2-Fold riseb N % 49 (28.5) 51 (27.7) 0.87
a Seroconversion was deﬁned as infant serum anti-VP6 IgA antibody level of ≥20 IU/mL 4 weeks after the second vaccine dose and a ≥4-fold rise from baseline.
b Deﬁned as infant serum anti-VP6 IgA antibody level of ≥20 IU/mL 4 weeks after the second vaccine dose and a ≥2-fold rise in the anti-VP6 IgA antibody level from
baseline.
Table 4
Anti-rotavirus antibody levels in infants and mothers as predictors for anti-rotavirus serum IgA levels 4 weeks after dose 2 of Rotarix® in infants who were seronegative at
baseline.
Explanatory variables Crude estimates Adjusted estimatesa
Co-efﬁcient (95% CI) p value R-Squared Co-efﬁcient (95% CI) p value
Infant serum IgA baseline 0.50 (0.30,0.70) 0.000 0.063 0.49 (0.29, 0.69) <0.001
Maternal
Baseline mother serum IgA −0.17 (−0.33, −0.02) 0.031 0.013 – –
Baseline mother serum IgG −0.22 (−0.37, −0.06) 0.006 0.020 – –
Baseline breast milk IgA −0.23 (−0.38, −0.07) 0.004 0.023 – –
Baseline breast milk IgG −0.14 (−0.22, −0.06) 0.001 0.030 – –
Breast milk IgA at dose 2 −0.26 (−0.42, −0.11) 0.001 0.031 −0.20 (−0.36, −0.05) 0.010











cog transformed anti-rotavirus concentrations.
a The adjusted estimates are the results of a multiple linear regression model w
ere  retained in the ﬁnal model.
erum IgA at baseline and lower odds of seroconversion with
ncreasing levels of maternal antibodies (Table 5).
. DiscussionWe  examined the effect of temporarily withholding breastfeed-
ng on the immune response to the live oral rotavirus vaccine
otarix® in a randomized community trial. Despite excellent
able 5
nti-rotavirus antibody concentration in infants and mothers as predictors for sero-
onversion 4 weeks after dose 2 of Rotarix® in infants seronegative at baseline.
Explanatory variables Crude estimates
Odds ratio (95% CI) p value
Infant
Infant serum IgA baseline 1.24 (0.92–1.68) 0.162
Maternal
Baseline mother serum IgA 0.82 (0.65–1.03) 0.094
Baseline mother serum IgG 0.75 (0.60–0.93) 0.011
Baseline breast milk IgA 0.76 (0.59–0.97) 0.029
Baseline breast milk IgG 0.84 (0.75–0.96) 0.007
Breast milk IgA at dose 2 0.70 (0.54–0.91) 0.007
Breast milk IgG at dose 2 0.87 (0.77–0.98) 0.021 = 356, p < 0.001 adjusted r2 = 0.1047, only the variables that remained signiﬁcant
compliance to the breastfeeding instructions in the groups where
breastfeeding was  withheld as well as the group where breastfeed-
ing was encouraged, the proportion of infants who seroconverted
was similar in the two  groups. These results are similar to those
reported from similar studies in South Africa and Pakistan [18,21].
The overall seroconversion rate in our study was  low, and fac-
tors other than maternal antibodies are likely to be responsible for
the poor immunogenicity of the vaccine. A recent Rotarix® trial in
south India examined the effect of probiotic and zinc supplemen-
tation on the immune response to oral rotavirus and oral poliovirus
vaccines. This study reported a 35% seroconversion rate in infants
who received the vaccine with probiotic supplementation and 28%
in infants who  received the vaccine and a placebo. In children who
received the vaccine with zinc supplementation the seroconversion
rate was 34% compared to 29% in the group receiving the vaccine
and a placebo [20]. The infants in the study in south India were
of the same age as the infants in our study and in both studies
childhood vaccines were given along with Rotarix®. A low sero-
conversion rate was also seen in Pakistan where they examined
the immune response to Rotarix® after withholding breastfeeding
for an hour before and after giving the vaccine [21].
An immunogenicity study of Rotarix in India reported a 58.3%
seroconversion rate [22]. In this study, the mean age of infants at the
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nd 13.4 weeks of age, compared to 6 weeks in our study and in the
outh Indian study. Also, in this immunogenicity study, an interval
f two weeks was maintained between other childhood vaccines
nd the rotavirus vaccine whereas in our study and in the south
ndian study the childhood vaccines were given along with Rotarix.
imilar ﬁndings were seen with the Indian rotavirus vaccine, ORV
16E, where the immune response in the phase Ia/IIb was  much
igher than reported in the phase III (90% vs. 40%) [10,23]. In the
hase1a/IIb trial, infants were around 8 weeks old at the time of
eceiving the ﬁrst dose of the vaccine and there was in interval
f two weeks between childhood vaccines and 116E while in the
hase III trial, infants were around 6 weeks old and received the
hildhood vaccines along with the rotavirus vaccine.
It is possible that in both Rotarix and 116E immunogenicity
tudies the slightly higher age at vaccination and/or maintaining an
nterval between childhood vaccines and rotavirus vaccines partic-
larly the live oral polio vaccine, may  have improved the immune
esponse. It has been described before that co-administration of
ral poliovirus vaccine interferes with the immune response to
otavirus vaccines [19,24,25], although polio seroconversion rates
re not affected.
Other studies have reported inverse association seen between
aternal serum and breast milk IgA and IgG levels of infant IgA lev-
ls post dose 2. The 116E vaccine showed an inverse relationship
etween levels of pre-existing rotavirus IgG and immune response
o the vaccine [26]. In our study, preexisitng antibodies at baseline
xplained only about 10% of the variability in the immune response
o the vaccine. Although maternal antibodies impair the immuno-
enicity, other factors seem to be more important and contribute
o the poor immune response.
The protective role of maternal antibodies against rotavirus
nfection is not clear [13,14,27] although it is suggestive of pro-
ection [28,29]. In the previously mentioned study in Pakistan, the
eroconversion rate was higher in the group that was  breastfed
round the time of vaccination, although the difference was not sta-
istically signiﬁcant. Even if withholding breast milk at the time of
accination could modify the immune response, the impact would
e minimal as the maternal levels explained only a fraction of the
ariability in the immune responses.
A limitation of our study was that the duration of withhold-
ng breastfeeding around the time of vaccination was restricted to
0 min  before and after each dose. Studies have shown that half gas-
ric emptying time in infants who were breastfed varied between
7 and 56 min  [30–32]. Therefore, half of the breast milk would
till be present in the infant’s stomach after an hour. Withhold-
ng breastfeeding for an hour before and after vaccination would
ave been appropriate but was not feasible in this study setting.
his time interval was also used in the previously mentioned phase
a/II oral rotavirus vaccine 116E trial which demonstrated good
mmunogenicity [23]. However, the recent study from south Africa
uggest that increasing the window for withholding breastfeed-
ng does not effect the immune response [18]. Additionally, in this
tudy, only infants who were currently breastfed were enrolled. It
s possible that maternal antibodies transferred transplacentally or
hrough breast milk to the infant may  interfere with the immune
esponse even if mothers withhold breastfeeding around the time
f vaccination. The prevalence of exclusive breastfeeding was  high
t baseline, which is consistent with previous observations in this
opulation [33].
Seroconversion is not a direct indicator of clinical vaccine
fﬁcacy but it is nevertheless important as a proxy for vaccine
ptake. Mechanisms other than antibody levels may  explain the
ow immune response to rotavirus vaccines. It is worthwhile
o explore whether interference with other intestinal infections
r micronutrient deﬁciencies may  modify immune responses
34,35].
[ine 32S (2014) A134–A139
In conclusion, withholding breastfeeding around the time of
vaccination did not improve the immune response to Rotarix® in
Indian infants. This suggests that the interference of breast milk
with the vaccine ‘take’ as assumed previously may  not be of prac-
tical clinical relevance.
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